|
Research
Front Name
|
Percentage of corporate affiliations
|
Leading
corporation
|
|
EARLY DRUG DISCOVERY USING HIGH-RESOLUTION LIQUID
CHROMATOGRAPHY/QUADRUPOLE TIME-OF-FLIGHT MASS
SPECTROMETRY
|
47
|
Waters Corp.
|
|
VIRTUAL SCREENING; PROTEIN-LIGAND DOCKING; EVALUATING
VIRTUAL SCREENING METHODS; MOLECULAR DOCKING ACCURACY
|
28
|
Schrodinger, LLC
|
|
SUBOPTIMALLY CONTROLLED TYPE 2 DIABETES; TYPE 2
DIABETES PREVIOUSLY UNCONTROLLED; EXENATIDE TREATMENT
|
26
|
Amylin Pharmaceuticals, Inc.
|
|
TYPE 2 DIABETES; THIAZOLIDINEDIONE MONOTHERAPY;
DIPEPTIDYL PEPTIDASE-4 INHIBITOR VILDAGLIPTIN IMPROVES
BETA-CELL FUNCTION; TYPE 2 DIABETES INADEQUATELY
CONTROLLED
|
26
|
Merck & Co., Inc.
|
|
NONINFLAMMATORY SYNTHETIC SIRNA; POTENT GENE SILENCING
IN-VIVO; SYSTEMIC LEUKOCYTE-DIRECTED SIRNA DELIVERY;
SMALL INTERFERING RNA INHIBITS TUMOR GROWTH
|
26
|
Alnylam Pharmaceuticals, Inc.
|
|
MULTI-TARGET-DIRECTED DRUG DESIGN STRATEGY;
SYSTEMS-ORIENTED DRUG DESIGN; RATIONALLY DESIGN
PROMISCUOUS DRUGS; MULTI-TARGET-DIRECTED LIGANDS
|
25
|
Schering-Plough
|
|
GENE MENTION FINDING EVALUATION; BIOCREATIVE
ASSESSMENT; PROTEIN FUNCTION PREDICTION
|
22
|
MITRE Corp.
|
|
BIOLOGICAL TIME-OF-FLIGHT-SECONDARY ION MASS
SPECTROMETRY IMAGING; TISSUE MOLECULAR ION IMAGING;
GOLD CLUSTER ION BOMBARDMENT
|
21
|
Ionoptika Ltd.
|
|
TUMOUR SUPPRESSOR CYLD; NF-KAPPA B SIGNALLING;
NEGATIVELY REGULATES NF-KAPPA B ACTIVATION; NF-KAPPA B
PATHWAY
|
21
|
Genentech, Inc.
|
